Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. 
   ASHP therapeutic position statement on the safe use of pharmacotherapy forobesity management in adults
   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
   
   AM J HEAL S, 58(17), 2001, pp. 1645-1655
2. Campbell, ML; Mathys, ML
   Pharmacologic options for the treatment of obesity
   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
   
   M.L. Campbell e M.L. Mathys, "Pharmacologic options for the treatment of obesity", AM J HEAL S, 58(14), 2001, pp. 1301-1308
3. Starling, RD; Liu, XL; Sullivan, DH
   Influence of sibutramine on energy expenditure in African American women
   OBESITY RESEARCH
   
   R.D. Starling et al., "Influence of sibutramine on energy expenditure in African American women", OBES RES, 9(4), 2001, pp. 251-256
4. Womble, LG; Wadden, TA; Berkowitz, RI; Sarwer, DB; Rothman, RA
   Long-term medication use and weight loss maintenance: An observational study
   OBESITY RESEARCH
   
   L.G. Womble et al., "Long-term medication use and weight loss maintenance: An observational study", OBES RES, 9(10), 2001, pp. 652-653
5. Arterburn, D; Noel, PH
   Extracts from "Clinical Evidence" - Obesity
   BRITISH MEDICAL JOURNAL
   
   D. Arterburn e P.H. Noel, "Extracts from "Clinical Evidence" - Obesity", BR MED J, 322(7299), 2001, pp. 1406-1409
6. Yip, I; Go, VLW; Hershman, JM; Wang, HJ; Elashoff, R; DeShields, S; Liu, Y; Heber, D
   Insulin-leptin-visceral fat relation during weight loss
   PANCREAS
   
   I. Yip et al., "Insulin-leptin-visceral fat relation during weight loss", PANCREAS, 23(2), 2001, pp. 197-203
7. Campbell, L; Rossner, S
   Management of obesity in patients with Type 2 diabetes
   DIABETIC MEDICINE
   
   L. Campbell e S. Rossner, "Management of obesity in patients with Type 2 diabetes", DIABET MED, 18(5), 2001, pp. 345-354
8. Berube-Parent, S; Prud'homme, D; St-Pierre, S; Doucet, E; Tremblay, A
   Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet-exercise intervention
   INTERNATIONAL JOURNAL OF OBESITY
   
   S. Berube-Parent et al., "Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet-exercise intervention", INT J OBES, 25(8), 2001, pp. 1144-1153
9. Fanghanel, G; Cortinas, L; Sanchez-Reyes, L; Berber, A
   Second phase of a double-blind study clinical trial on Sibutramine for thetreatment of patients suffering essential obesity: 6 months after treatment cross-over
   INTERNATIONAL JOURNAL OF OBESITY
   
   G. Fanghanel et al., "Second phase of a double-blind study clinical trial on Sibutramine for thetreatment of patients suffering essential obesity: 6 months after treatment cross-over", INT J OBES, 25(5), 2001, pp. 741-747
10. Bailey, CJ; Turner, SL; Bates, SH; Jones, RB
    Sibutramine metabolites increase glucose transport by cultured rat muscle cells
    INTERNATIONAL JOURNAL OF OBESITY
    
    C.J. Bailey et al., "Sibutramine metabolites increase glucose transport by cultured rat muscle cells", INT J OBES, 25(4), 2001, pp. 478-485
11. Hansen, DL; Astrup, A; Toubro, S; Finer, N; Kopelman, P; Hilsted, J; Rossner, S; Saris, WHM; Van Gaal, LF; James, WPT; Goulder, M
    Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial
    INTERNATIONAL JOURNAL OF OBESITY
    
    D.L. Hansen et al., "Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial", INT J OBES, 25(4), 2001, pp. 496-501
12. Boozer, CN; Nasser, JA; Heymsfield, SB; Wang, V; Chen, G; Solomon, JL
    An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial
    INTERNATIONAL JOURNAL OF OBESITY
    
    C.N. Boozer et al., "An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial", INT J OBES, 25(3), 2001, pp. 316-324
13. Prow, MR; Lancashire, B; Aspley, S; Heal, DJ; Kilpatrick, IC
    Additive effects on rat brain 5HT release of combining phentermine with dexfenfluramine
    INTERNATIONAL JOURNAL OF OBESITY
    
    M.R. Prow et al., "Additive effects on rat brain 5HT release of combining phentermine with dexfenfluramine", INT J OBES, 25(10), 2001, pp. 1450-1453
14. Kilpatrick, IC; Traut, M; Heal, DJ
    Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release
    INTERNATIONAL JOURNAL OF OBESITY
    
    I.C. Kilpatrick et al., "Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release", INT J OBES, 25(10), 2001, pp. 1454-1458
15. Hauner, H
    Current pharmacological approaches to the treatment of obesity
    INTERNATIONAL JOURNAL OF OBESITY
    
    H. Hauner, "Current pharmacological approaches to the treatment of obesity", INT J OBES, 25, 2001, pp. S102-S106
16. Collins, P; Williams, G
    Drug treatment of obesity: from past failures to future successes?
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    P. Collins e G. Williams, "Drug treatment of obesity: from past failures to future successes?", BR J CL PH, 51(1), 2001, pp. 13-25
17. Clapham, JC; Arch, JRS; Tadayyon, M
    Anti-obesity drugs: a critical review of current therapies and future opportunities
    PHARMACOLOGY & THERAPEUTICS
    
    J.C. Clapham et al., "Anti-obesity drugs: a critical review of current therapies and future opportunities", PHARM THERA, 89(1), 2001, pp. 81-121
18. Smith, IG; Goulder, MA
    Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity
    JOURNAL OF FAMILY PRACTICE
    
    I.G. Smith e M.A. Goulder, "Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity", J FAM PRACT, 50(6), 2001, pp. 505-512
19. Brown, M; Bing, C; King, P; Pickavance, L; Heal, D; Wilding, J
    Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wister rats independently of hypothalamic neuropeptide Y
    BRITISH JOURNAL OF PHARMACOLOGY
    
    M. Brown et al., "Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wister rats independently of hypothalamic neuropeptide Y", BR J PHARM, 132(8), 2001, pp. 1898-1904
20. Wadden, TA; Berkowitz, RI; Sarwer, DB; Prus-Wisniewski, R; Steinberg, C
    Benefits of lifestyle modification in the pharmacologic treatment of obesity - A randomized trial
    ARCHIVES OF INTERNAL MEDICINE
    
    T.A. Wadden et al., "Benefits of lifestyle modification in the pharmacologic treatment of obesity - A randomized trial", ARCH IN MED, 161(2), 2001, pp. 218-227
21. Scheen, AJ; Lefebvre, PJ
    Antiobesity pharmacotherapy in the management of Type 2 diabetes
    DIABETES-METABOLISM RESEARCH AND REVIEWS
    
    A.J. Scheen e P.J. Lefebvre, "Antiobesity pharmacotherapy in the management of Type 2 diabetes", DIABET M R, 16(2), 2000, pp. 114-124
22. Fujioka, K; Seaton, TB; Rowe, E; Jelinek, CA; Raskin, P; Lebovitz, HE; Weinstein, SP
    Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus
    DIABETES OBESITY & METABOLISM
    
    K. Fujioka et al., "Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus", DIABET OB M, 2(3), 2000, pp. 175-187
23. Finer, N; Bloom, SR; Frost, GS; Banks, LM; Griffiths, J
    Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study
    DIABETES OBESITY & METABOLISM
    
    N. Finer et al., "Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study", DIABET OB M, 2(2), 2000, pp. 105-112
24. Astrup, A
    Thermogenic drugs as a strategy for treatment of obesity
    ENDOCRINE
    
    A. Astrup, "Thermogenic drugs as a strategy for treatment of obesity", ENDOCRINE, 13(2), 2000, pp. 207-212
25. Nakagawa, T; Ukai, K; Ohyama, T; Gomita, Y; Okamura, H
    Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: Relationship of antiobesity effect with monoamines
    EXPERIMENTAL ANIMALS
    
    T. Nakagawa et al., "Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: Relationship of antiobesity effect with monoamines", EXP ANIM, 49(4), 2000, pp. 239-249
26. Ziegler, O; Quilliot, D
    Drug therapy of obesity in type 2 diabetes mellitus.
    DIABETES & METABOLISM
    
    O. Ziegler e D. Quilliot, "Drug therapy of obesity in type 2 diabetes mellitus.", DIABETE MET, 26, 2000, pp. 34-41
27. Wadden, TA; Berkowitz, RI; Womble, LG; Sarwer, DB; Arnold, ME; Steinberg, CM
    Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: A placebo-controlled trial
    OBESITY RESEARCH
    
    T.A. Wadden et al., "Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: A placebo-controlled trial", OBES RES, 8(6), 2000, pp. 431-437
28. Hirsch, J; Mackintosh, RM; Aronne, LJ
    The effects of drugs used to treat obesity on the autonomic nervous system
    OBESITY RESEARCH
    
    J. Hirsch et al., "The effects of drugs used to treat obesity on the autonomic nervous system", OBES RES, 8(3), 2000, pp. 227-233
29. Cuellar, GEM; Ruiz, AM; Monsalve, MCR; Berber, A
    Six-month treatment of obesity with sibutramine 15 mg; A double-blind, placebo-controlled monocenter clinical trial in a Hispanic population
    OBESITY RESEARCH
    
    G.E.M. Cuellar et al., "Six-month treatment of obesity with sibutramine 15 mg; A double-blind, placebo-controlled monocenter clinical trial in a Hispanic population", OBES RES, 8(1), 2000, pp. 71-82
30. Bray, GA
    A concise review on the therapeutics of obesity
    NUTRITION
    
    G.A. Bray, "A concise review on the therapeutics of obesity", NUTRITION, 16(10), 2000, pp. 953-960
31. Greenway, FL; Smith, SR
    The future of obesity research
    NUTRITION
    
    F.L. Greenway e S.R. Smith, "The future of obesity research", NUTRITION, 16(10), 2000, pp. 976-982
32. Rowley, HL; Butler, S; Prow, MR; Dykes, SG; Aspley, S; Kilpatrick, IC; Heal, DJ
    Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats
    SYNAPSE
    
    H.L. Rowley et al., "Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats", SYNAPSE, 38(2), 2000, pp. 167-176
33. Wilding, J
    Obesity and Type 2 diabetes mellitus
    DIABETIC MEDICINE
    
    J. Wilding, "Obesity and Type 2 diabetes mellitus", DIABET MED, 17(5), 2000, pp. 400-402
34. Radhakrishna, T; Narayana, CL; Rao, DS; Vyas, K; Reddy, GO
    LC method for the determination of assay and purity of sibutramine hydrochloride and its enantiomers by chiral chromatography
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
    
    T. Radhakrishna et al., "LC method for the determination of assay and purity of sibutramine hydrochloride and its enantiomers by chiral chromatography", J PHARM B, 22(4), 2000, pp. 627-639
35. Fanghanel, G; Cortinas, L; Sanchez-Reyes, L; Berber, A
    A clinical trial of the use of Sibutramine for the treatment of patients suffering essential obesity
    INTERNATIONAL JOURNAL OF OBESITY
    
    G. Fanghanel et al., "A clinical trial of the use of Sibutramine for the treatment of patients suffering essential obesity", INT J OBES, 24(2), 2000, pp. 144-150
36. Fabris, R; Granzotto, M; Pagano, C; Lombardi, AM; Ferretti, E; Marzolo, M; Scagnol, I; Federspil, G; Vettor, R
    Effect of sibutramine on glucose metabolism in genetically obese (fa/fa) Zucker rats
    INTERNATIONAL JOURNAL OF OBESITY
    
    R. Fabris et al., "Effect of sibutramine on glucose metabolism in genetically obese (fa/fa) Zucker rats", INT J OBES, 24, 2000, pp. S124-S126
37. Wesnes, KA; Garratt, C; Wickens, M; Gudgeon, A; Oliver, S
    Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    K.A. Wesnes et al., "Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers", BR J CL PH, 49(2), 2000, pp. 110-117
38. Rothman, RB; Carroll, FI
    Opportunities for medication development in obesity
    DRUG DEVELOPMENT RESEARCH
    
    R.B. Rothman e F.I. Carroll, "Opportunities for medication development in obesity", DRUG DEV R, 51(2), 2000, pp. 49-51
39. Ryan, DH
    Recent progress in obesity pharmacotherapy
    CURRENT OPINION IN GASTROENTEROLOGY
    
    D.H. Ryan, "Recent progress in obesity pharmacotherapy", CURR OPIN G, 16(2), 2000, pp. 166-172
40. Agrawal, M; Worzniak, M; Diamond, L
    Managing obesity like any other chronic condition - Long-term therapy may reduce comorbidity as well
    POSTGRADUATE MEDICINE
    
    M. Agrawal et al., "Managing obesity like any other chronic condition - Long-term therapy may reduce comorbidity as well", POSTGR MED, 108(1), 2000, pp. 75
41. Mattes, RD; Bormann, L
    Effects of (-)-hydroxycitric acid on appetitive variables
    PHYSIOLOGY & BEHAVIOR
    
    R.D. Mattes e L. Bormann, "Effects of (-)-hydroxycitric acid on appetitive variables", PHYSL BEHAV, 71(1-2), 2000, pp. 87-94
42. Chapelot, D; Marmonier, C; Thomas, F; Hanotin, C
    Modalities of the food intake-reducing effect of sibutramine in humans
    PHYSIOLOGY & BEHAVIOR
    
    D. Chapelot et al., "Modalities of the food intake-reducing effect of sibutramine in humans", PHYSL BEHAV, 68(3), 2000, pp. 299-308
43. Balcioglu, A; Wurtman, RJ
    Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid
    NEUROPHARMACOLOGY
    
    A. Balcioglu e R.J. Wurtman, "Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid", NEUROPHARM, 39(12), 2000, pp. 2352-2359
44. Cheetham, SC; Viggers, JA; Slater, NA; Heal, DJ
    Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine
    NEUROPHARMACOLOGY
    
    S.C. Cheetham et al., "Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine", NEUROPHARM, 39(11), 2000, pp. 2028-2035
45. 
    SEEDO ' 2000 consensus for the evaluation of overweight and obesity and the assessment of obesity management
    MEDICINA CLINICA
    
    MED CLIN, 115(15), 2000, pp. 587-597
46. Hensrud, DD
    Pharmacotherapy for obesity
    MEDICAL CLINICS OF NORTH AMERICA
    
    D.D. Hensrud, "Pharmacotherapy for obesity", MED CLIN NA, 84(2), 2000, pp. 463
47. Trent, ME; Laufer, MR
    Obesity in adolescent girls - Emerging role of reproductive health professionals
    JOURNAL OF REPRODUCTIVE MEDICINE
    
    M.E. Trent e M.R. Laufer, "Obesity in adolescent girls - Emerging role of reproductive health professionals", J REPRO MED, 45(6), 2000, pp. 445-453
48. Glick, SD; Haskew, RE; Maisonneuve, IM; Carlson, JN; Jerussi, TP
    Enantioselective behavioral effects of sibutramine metabolites
    EUROPEAN JOURNAL OF PHARMACOLOGY
    
    S.D. Glick et al., "Enantioselective behavioral effects of sibutramine metabolites", EUR J PHARM, 397(1), 2000, pp. 93-102
49. Hazenberg, BP
    Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients
    CARDIOLOGY
    
    B.P. Hazenberg, "Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients", CARDIOLOGY, 94(3), 2000, pp. 152-158
50. Lean, MEJ
    Is long-term weight loss possible?
    BRITISH JOURNAL OF NUTRITION
    
    M.E.J. Lean, "Is long-term weight loss possible?", BR J NUTR, 83, 2000, pp. S103-S111
51. Berke, EM; Morden, NE
    Medical management of obesity
    AMERICAN FAMILY PHYSICIAN
    
    E.M. Berke e N.E. Morden, "Medical management of obesity", AM FAM PHYS, 62(2), 2000, pp. 419-426
52. Poston, WSC; Foreyt, JP
    Successful management of the obese patient
    AMERICAN FAMILY PHYSICIAN
    
    W.S.C. Poston e J.P. Foreyt, "Successful management of the obese patient", AM FAM PHYS, 61(12), 2000, pp. 3615-3622
53. Rowland, NE; Marshall, M; Roth, JD
    Comparison of either norepinephrine-uptake inhibitors or phentermine combined with serotonergic agents on food intake in rats
    PSYCHOPHARMACOLOGY
    
    N.E. Rowland et al., "Comparison of either norepinephrine-uptake inhibitors or phentermine combined with serotonergic agents on food intake in rats", PSYCHOPHAR, 149(1), 2000, pp. 77-83
54. Schuh, LM; Schuster, CR; Hopper, JA; Mendel, CM
    Abase liability assessment of sibutramine, a novel weight control agent
    PSYCHOPHARMACOLOGY
    
    L.M. Schuh et al., "Abase liability assessment of sibutramine, a novel weight control agent", PSYCHOPHAR, 147(4), 2000, pp. 339-346
55. Ellrott, T
    Current efforts in the drug treatment of obesity
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
    
    T. Ellrott, "Current efforts in the drug treatment of obesity", DEUT MED WO, 125(9), 2000, pp. 256-261
56. Leong, KS; Wilding, JP
    Obesity and diabetes
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
    
    K.S. Leong e J.P. Wilding, "Obesity and diabetes", BEST PRAC R, 13(2), 1999, pp. 221-237
57. Bray, GA
    Drug treatment of obesity
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
    
    G.A. Bray, "Drug treatment of obesity", BEST PRAC R, 13(1), 1999, pp. 131-148
58. Tremblay, A; Doucet, E; Imbeault, P; Mauriege, P; Despres, JP; Richard, D
    Metabolic fitness in active reduced-obese individuals
    OBESITY RESEARCH
    
    A. Tremblay et al., "Metabolic fitness in active reduced-obese individuals", OBES RES, 7(6), 1999, pp. 556-563
59. Bray, GA
    Uses and misuses of the new pharmacotherapy of obesity
    ANNALS OF MEDICINE
    
    G.A. Bray, "Uses and misuses of the new pharmacotherapy of obesity", ANN MED, 31(1), 1999, pp. 1-3
60. Walsh, KM; Leen, E; Lean, MEJ
    The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females
    INTERNATIONAL JOURNAL OF OBESITY
    
    K.M. Walsh et al., "The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females", INT J OBES, 23(10), 1999, pp. 1009-1015
61. Hansen, DL; Toubro, S; Stock, MJ; Macdonald, IA; Astrup, A
    The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction
    INTERNATIONAL JOURNAL OF OBESITY
    
    D.L. Hansen et al., "The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction", INT J OBES, 23(10), 1999, pp. 1016-1024
62. Greenberg, I; Chan, S; Blackburn, GL
    Nonpharmacologic and pharmacologic management of weight gain
    JOURNAL OF CLINICAL PSYCHIATRY
    
    I. Greenberg et al., "Nonpharmacologic and pharmacologic management of weight gain", J CLIN PSY, 60, 1999, pp. 31-36
63. Hind, ID; Mangham, JE; Ghani, SP; Haddock, RE; Garratt, CJ; Jones, RW
    Sibutramine pharmacokinetics in young and elderly healthy subjects
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    
    I.D. Hind et al., "Sibutramine pharmacokinetics in young and elderly healthy subjects", EUR J CL PH, 54(11), 1999, pp. 847-849
64. Berg, FM
    Health risks associated with weight loss and obesity treatment programs
    JOURNAL OF SOCIAL ISSUES
    
    F.M. Berg, "Health risks associated with weight loss and obesity treatment programs", J SOC ISSUE, 55(2), 1999, pp. 277-297
65. Gray, AM; Pache, DM; Sewell, RDE
    Do alpha(2)-adrenoceptors play an integral role in the antinociceptive mechanism of action of antidepressant compounds?
    EUROPEAN JOURNAL OF PHARMACOLOGY
    
    A.M. Gray et al., "Do alpha(2)-adrenoceptors play an integral role in the antinociceptive mechanism of action of antidepressant compounds?", EUR J PHARM, 378(2), 1999, pp. 161-168
66. Wortley, KE; Heal, DJ; Stanford, SC
    Modulation of sibutramine-induced increases in extracellular noradrenalineconcentration in rat frontal cortex and hypothalamus by alpha(2)-adrenoceptors
    BRITISH JOURNAL OF PHARMACOLOGY
    
    K.E. Wortley et al., "Modulation of sibutramine-induced increases in extracellular noradrenalineconcentration in rat frontal cortex and hypothalamus by alpha(2)-adrenoceptors", BR J PHARM, 128(3), 1999, pp. 659-666
67. Wortley, KE; Hughes, ZA; Heal, DJ; Stanford, SC
    Comparison of changes in the extracellular concentration of noradrenaline in rat frontal cortex induced by sibutramine or d-amphetamine: modulation by alpha(2)-adrenoceptors
    BRITISH JOURNAL OF PHARMACOLOGY
    
    K.E. Wortley et al., "Comparison of changes in the extracellular concentration of noradrenaline in rat frontal cortex induced by sibutramine or d-amphetamine: modulation by alpha(2)-adrenoceptors", BR J PHARM, 127(8), 1999, pp. 1860-1866
68. Grignaschi, G; Fanelli, E; Scagnol, I; Samanin, R
    Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats
    BRITISH JOURNAL OF PHARMACOLOGY
    
    G. Grignaschi et al., "Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats", BR J PHARM, 127(5), 1999, pp. 1190-1194
69. Connoley, IP; Liu, YL; Frost, I; Reckless, IP; Heal, DJ; Stock, MJ
    Thermogenic effects of sibutramine and its metabolites
    BRITISH JOURNAL OF PHARMACOLOGY
    
    I.P. Connoley et al., "Thermogenic effects of sibutramine and its metabolites", BR J PHARM, 126(6), 1999, pp. 1487-1495
70. Van Gaal, LF; Peiffer, FW; De Leeuw, IH
    New pharmacological directions for the treatment of overweight and obesity
    ACTA CLINICA BELGICA
    
    L.F. Van Gaal et al., "New pharmacological directions for the treatment of overweight and obesity", ACT CLIN B, 54(3), 1999, pp. 141-146
71. SEAGLE HM; BESSESEN DH; HILL JO
    EFFECTS OF SIBUTRAMINE ON RESTING METABOLIC-RATE AND WEIGHT-LOSS IN OVERWEIGHT WOMEN
    Obesity research
    
    H.M. Seagle et al., "EFFECTS OF SIBUTRAMINE ON RESTING METABOLIC-RATE AND WEIGHT-LOSS IN OVERWEIGHT WOMEN", Obesity research, 6(2), 1998, pp. 115-121
72. ROLLS BJ; SHIDE DJ; THORWART ML; ULBRECHT JS
    SIBUTRAMINE REDUCES FOOD-INTAKE IN NON-DIETING WOMEN WITH OBESITY
    Obesity research
    
    B.J. Rolls et al., "SIBUTRAMINE REDUCES FOOD-INTAKE IN NON-DIETING WOMEN WITH OBESITY", Obesity research, 6(1), 1998, pp. 1-11
73. ATKINSON RL
    GUIDELINES FOR THE INITIATION OF OBESITY TREATMENT
    Journal of nutritional biochemistry
    
    R.L. Atkinson, "GUIDELINES FOR THE INITIATION OF OBESITY TREATMENT", Journal of nutritional biochemistry, 9(10), 1998, pp. 546-552
74. VANGAAL LF; WAUTERS MA; DELEEUW IH
    ANTIOBESITY DRUGS - WHAT DOES SIBUTRAMINE OFFER - AN ANALYSIS OF ITS POTENTIAL CONTRIBUTION TO OBESITY TREATMENT
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
    
    L.F. Vangaal et al., "ANTIOBESITY DRUGS - WHAT DOES SIBUTRAMINE OFFER - AN ANALYSIS OF ITS POTENTIAL CONTRIBUTION TO OBESITY TREATMENT", EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 106, 1998, pp. 35-39
75. DAY C; BAILEY CJ
    EFFECT OF THE ANTIOBESITY AGENT SIBUTRAMINE IN OBESE-DIABETIC OB OB MICE/
    International journal of obesity
    
    C. Day e C.J. Bailey, "EFFECT OF THE ANTIOBESITY AGENT SIBUTRAMINE IN OBESE-DIABETIC OB OB MICE/", International journal of obesity, 22(7), 1998, pp. 619-623
76. HANOTIN C; THOMAS F; JONES SP; LEUTENEGGER E; DROUIN P
    EFFICACY AND TOLERABILITY OF SIBUTRAMINE IN OBESE PATIENTS - A DOSE-RANGING STUDY
    International journal of obesity
    
    C. Hanotin et al., "EFFICACY AND TOLERABILITY OF SIBUTRAMINE IN OBESE PATIENTS - A DOSE-RANGING STUDY", International journal of obesity, 22(1), 1998, pp. 32-38
77. HEAL DJ; ASPLEY S; PROW MR; JACKSON HC; MARTIN KF; CHEETHAM SC
    SIBUTRAMINE - A NOVEL ANTIOBESITY DRUG - A REVIEW OF THE PHARMACOLOGICAL EVIDENCE TO DIFFERENTIATE IT FROM D-AMPHETAMINE AND D-FENFLURAMINE
    International journal of obesity
    
    D.J. Heal et al., "SIBUTRAMINE - A NOVEL ANTIOBESITY DRUG - A REVIEW OF THE PHARMACOLOGICAL EVIDENCE TO DIFFERENTIATE IT FROM D-AMPHETAMINE AND D-FENFLURAMINE", International journal of obesity, 22, 1998, pp. 18-28
78. ASTRUP A; HANSEN DL; LUNDSGAARD C; TOUBRO S
    SIBUTRAMINE AND ENERGY-BALANCE
    International journal of obesity
    
    A. Astrup et al., "SIBUTRAMINE AND ENERGY-BALANCE", International journal of obesity, 22, 1998, pp. 30-35
79. VANGAAL LF; WAUTERS MA; PEIFFER FW; DELEEUW IH
    SIBUTRAMINE AND FAT DISTRIBUTION - IS THERE A ROLE FOR PHARMACOTHERAPY IN ABDOMINAL VISCERAL FAT REDUCTION/
    International journal of obesity
    
    L.F. Vangaal et al., "SIBUTRAMINE AND FAT DISTRIBUTION - IS THERE A ROLE FOR PHARMACOTHERAPY IN ABDOMINAL VISCERAL FAT REDUCTION/", International journal of obesity, 22, 1998, pp. 38-40
80. Astrup, A
    Sibutramine, a forthcoming drug, induces weight loss by reduction of energy intake and increase of energy expenditure
    ACTA MEDICA AUSTRIACA
    
    A. Astrup, "Sibutramine, a forthcoming drug, induces weight loss by reduction of energy intake and increase of energy expenditure", ACT MED AUS, 25(4-5), 1998, pp. 146-149
81. HALFORD JCG; WANNINAYAKE SCD; BLUNDELL JE
    BEHAVIORAL SATIETY SEQUENCE (BSS) FOR THE DIAGNOSIS OF DRUG-ACTION ONFOOD-INTAKE
    Pharmacology, biochemistry and behavior
    
    J.C.G. Halford et al., "BEHAVIORAL SATIETY SEQUENCE (BSS) FOR THE DIAGNOSIS OF DRUG-ACTION ONFOOD-INTAKE", Pharmacology, biochemistry and behavior, 61(2), 1998, pp. 159-168
82. McNeely, W; Goa, KL
    Sibutramine - A review of its contribution to the management of obesity
    DRUGS
    
    W. McNeely e K.L. Goa, "Sibutramine - A review of its contribution to the management of obesity", DRUGS, 56(6), 1998, pp. 1093-1124
83. HEAL DJ; CHEETHAM SC; PROW MR; MARTIN KF; BUCKETT WR
    A COMPARISON OF THE EFFECTS ON CENTRAL 5-HT FUNCTION OF SIBUTRAMINE HYDROCHLORIDE AND OTHER WEIGHT-MODIFYING AGENTS
    British Journal of Pharmacology
    
    D.J. Heal et al., "A COMPARISON OF THE EFFECTS ON CENTRAL 5-HT FUNCTION OF SIBUTRAMINE HYDROCHLORIDE AND OTHER WEIGHT-MODIFYING AGENTS", British Journal of Pharmacology, 125(2), 1998, pp. 301-308
84. JACKSON HC; CHEETHAM SC; GOSDEN J; HUTCHINS LJ; KERRIGAN F; NEEDHAM AM; PLEASANCE IM; SARGENT BJ; HEAL DJ
    BEHAVIORAL-EFFECTS OF THE MONOAMINE REUPTAKE INHIBITOR, BTS-74398, INRATS AND MICE
    British Journal of Pharmacology
    
    H.C. Jackson et al., "BEHAVIORAL-EFFECTS OF THE MONOAMINE REUPTAKE INHIBITOR, BTS-74398, INRATS AND MICE", British Journal of Pharmacology, 123, 1998, pp. 256-256
85. Hansen, DL; Toubro, S; Stock, MJ; Macdonald, IA; Astrup, A
    Thermogenic effects of sibutramine in humans
    AMERICAN JOURNAL OF CLINICAL NUTRITION
    
    D.L. Hansen et al., "Thermogenic effects of sibutramine in humans", AM J CLIN N, 68(6), 1998, pp. 1180-1186
86. LEAN MEJ
    SIBUTRAMINE - A REVIEW OF CLINICAL EFFICACY
    International journal of obesity
    
    M.E.J. Lean, "SIBUTRAMINE - A REVIEW OF CLINICAL EFFICACY", International journal of obesity, 21, 1997, pp. 30-36
87. JACKSON HC; BEARHAM MC; HUTCHINS LJ; MAZURKIEWICZ SE; NEEDHAM AM; HEAL DJ
    INVESTIGATION OF THE MECHANISMS UNDERLYING THE HYPOPHAGIC EFFECTS OF THE 5-HT AND NORADRENALINE REUPTAKE INHIBITOR, SIBUTRAMINE, IN THE RAT
    British Journal of Pharmacology
    
    H.C. Jackson et al., "INVESTIGATION OF THE MECHANISMS UNDERLYING THE HYPOPHAGIC EFFECTS OF THE 5-HT AND NORADRENALINE REUPTAKE INHIBITOR, SIBUTRAMINE, IN THE RAT", British Journal of Pharmacology, 121(8), 1997, pp. 1613-1618
88. JACKSON HC; NEEDHAM AM; HUTCHINS LJ; MAZURKIEWICZ SE; HEAL DJ
    COMPARISON OF THE EFFECTS OF SIBUTRAMINE AND OTHER MONOAMINE REUPTAKEINHIBITORS ON FOOD-INTAKE IN RAT THE
    British Journal of Pharmacology
    
    H.C. Jackson et al., "COMPARISON OF THE EFFECTS OF SIBUTRAMINE AND OTHER MONOAMINE REUPTAKEINHIBITORS ON FOOD-INTAKE IN RAT THE", British Journal of Pharmacology, 121(8), 1997, pp. 1758-1762
89. CHEETHAM SC; VIGGERS JA; BUTLER SA; PROW MR; HEAL DJ
    [H-3] NISOXETINE - A RADIOLIGAND FOR NORADRENALINE REUPTAKE SITES - CORRELATION WITH INHIBITION OF [H-3] NORADRENALINE UPTAKE AND EFFECT OFDSP-4 LESIONING AND ANTIDEPRESSANT TREATMENTS
    Neuropharmacology
    
    S.C. Cheetham et al., "[H-3] NISOXETINE - A RADIOLIGAND FOR NORADRENALINE REUPTAKE SITES - CORRELATION WITH INHIBITION OF [H-3] NORADRENALINE UPTAKE AND EFFECT OFDSP-4 LESIONING AND ANTIDEPRESSANT TREATMENTS", Neuropharmacology, 35(1), 1996, pp. 63-70
90. BLUNDELL JE; HALFORD JCG
    PHARMACOLOGICAL ASPECTS OF OBESITY TREATMENT - TOWARDS THE 21ST-CENTURY
    International journal of obesity
    
    J.E. Blundell e J.C.G. Halford, "PHARMACOLOGICAL ASPECTS OF OBESITY TREATMENT - TOWARDS THE 21ST-CENTURY", International journal of obesity, 19, 1995, pp. 51-55
91. MARTIN KF; PHILLIPS I; CHEETHAM SC; HEAL DJ
    DOPAMINE D-2 RECEPTORS - A POTENTIAL PHARMACOLOGICAL TARGET FOR NOMIFENSINE AND TRANYLCYPROMINE BUT NOT OTHER ANTIDEPRESSANT TREATMENTS
    Pharmacology, biochemistry and behavior
    
    K.F. Martin et al., "DOPAMINE D-2 RECEPTORS - A POTENTIAL PHARMACOLOGICAL TARGET FOR NOMIFENSINE AND TRANYLCYPROMINE BUT NOT OTHER ANTIDEPRESSANT TREATMENTS", Pharmacology, biochemistry and behavior, 51(4), 1995, pp. 565-569
92. OGILVIE J; CHEETHAM SC; GOSDEN J; BUTLER SA; HEAL DJ
    EVIDENCE THAT OPIOIDS ARE NOT INVOLVED IN THE DOWN-REGULATION OF CENTRAL BETA-1-ADRENOCEPTORS AND ALPHA-2-ADRENOCEPTORS BY SIMULATED ELECTROCONVULSIVE-THERAPY
    British Journal of Pharmacology
    
    J. Ogilvie et al., "EVIDENCE THAT OPIOIDS ARE NOT INVOLVED IN THE DOWN-REGULATION OF CENTRAL BETA-1-ADRENOCEPTORS AND ALPHA-2-ADRENOCEPTORS BY SIMULATED ELECTROCONVULSIVE-THERAPY", British Journal of Pharmacology, 114, 1995, pp. 409-409
93. DAVIS S; HEAL DJ; STANFORD SC
    LONG-LASTING EFFECTS OF AN ACUTE STRESS ON THE NEUROCHEMISTRY AND FUNCTION OF 5-HYDROXYTRYPTAMINERGIC NEURONS IN THE MOUSE-BRAIN
    Psychopharmacology
    
    S. Davis et al., "LONG-LASTING EFFECTS OF AN ACUTE STRESS ON THE NEUROCHEMISTRY AND FUNCTION OF 5-HYDROXYTRYPTAMINERGIC NEURONS IN THE MOUSE-BRAIN", Psychopharmacology, 118(3), 1995, pp. 267-272
94. SCOTT G; LUSCOMBE GP; MASON R
    THE EFFECTS OF BTS-54-505, A METABOLITE OF SIBUTRAMINE, ON MONOAMINE AND EXCITATORY AMINO ACID-EVOKED RESPONSES IN THE RAT DORSOLATERAL GENICULATE-NUCLEUS IN-VIVO
    British Journal of Pharmacology
    
    G. Scott et al., "THE EFFECTS OF BTS-54-505, A METABOLITE OF SIBUTRAMINE, ON MONOAMINE AND EXCITATORY AMINO ACID-EVOKED RESPONSES IN THE RAT DORSOLATERAL GENICULATE-NUCLEUS IN-VIVO", British Journal of Pharmacology, 111(1), 1994, pp. 97-102
95. CHEETHAM SC; VIGGERS JA; SLATER NA; HEAL DJ; BUCKETT WR
    H-3! PAROXETINE BINDING IN RAT FRONTAL-CORTEX STRONGLY CORRELATES WITH H-3! 5-HT UPTAKE - EFFECT OF ADMINISTRATION OF VARIOUS ANTIDEPRESSANT TREATMENTS
    Neuropharmacology
    
    S.C. Cheetham et al., "H-3! PAROXETINE BINDING IN RAT FRONTAL-CORTEX STRONGLY CORRELATES WITH H-3! 5-HT UPTAKE - EFFECT OF ADMINISTRATION OF VARIOUS ANTIDEPRESSANT TREATMENTS", Neuropharmacology, 32(8), 1993, pp. 737-743